Polymyalgia rheumatica (PMR) is a distinct clinical syndrome. It was first described by Bruce liver biopsy had been carried out in 3 patients and temporal artery biopsy in 4 patients.
Results
Of the 36 patients there were 9 males and 27 females aged between 60 and 80 years, mean age 67. The ESR ranged from 49 to 134 mm in the first hour. In all patients studied the serum bilirubin, AST, ALT, and plasma proteins, were within normal limits.
Twenty patients (55%, had raised alkaline phosphatase, and, of these, 11 (55%) had a raised 5-nucleotidase. Eleven of the 36 patients (31%) had circulating antimitochondrial antibodies (AMA) in titres ranging from 1/20 to 1/8000. In the 3 liver biopsies nonspecific histological changes were seen, denoting a mild hepatitis. However, as only one of these patients had circulating AMA (titre 1:2500), no conclusions can be drawn. Four patients had cranial arteritis, confirmed by biopsy, of whom only one had AMA in a low titre of 1:20. There was no correlation between any of the hepatic changes and either the ESR or the clinical state, nor between the titres of AMA and other features (Table 1 ). There was also no significant difference in hepatic abnormality between AMA-positive and AMA-negative polymyalgia rheumatica patients.
Discussion
Boersma and Kerst6 first reported raised levels of alkaline phosphatase and increased bromsulph-thalein retention in patients with 'anarthritic rheumatoid arthritis (polymyalgia rheumatica)', and since then there have been several reports of disordered liver function in PMR, most commonly a raised serum ALP level. Our finding of raised ALP in 55% of patients is in general agreement with other reports.3' The rise in ALP is thought to denote a mild nonspecific involvement of the liver, and may be accompanied by nonspecific histological changes, such as were found in the 3 liver biopsies referred to above.
Glick' also noticed an unexpected incidence of antimitochondrial antibodies in patients with polymyalgia rheumatica. In our 11 AMA-positive patients with PMR the titre of AMA varied widely and was greater than 1/40 in 7 cases. The titres of AMA did not correlate with the ESR or ALP. AMA are considered to be strongly suggestive of PBC,9 and they occur in less than 0 1% of the general population.10 However, AMA are also found in about 20% of patients with chronic active hepatitis and in some with cryptogenic cirrhosis.1' In our hands between 2 and 3% of routine autoantibody examinations requested by clinicians show AMA, and apart from hepatic disease the incidence has been highest in rheumatoid arthritis and Hashimoto's thyroiditis. '2 Overlap between different autoimmune disorders is known to exist clinically. Serological overlap is more common. The relationship between PMR and PBC may be similar. While occasional unequivocal cases of the 2 disorders may coexist, serological and subclinical overlap may be more common. This is suggested by our study, which shows a high prevalence of serological and biochemical features of PBC in a selected group of patients with PMR. The interpretation of these findings is complicated by the lack of precise criteria for a diagnosis of PBC in the absence of characteristic histological changes, since biopsy tissue is often not available, and the diagnosis then rests on clinical judgment." Theoretically AMA production could also be provoked by damage to mitochondria in cells of nonhepatic origin. It antimitochondrial antibodies. 
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